Pfic

Educational clinical summary of Pfic for doctors and students: definition, workup, management, and key caveats. Not a substitute for guidelines.

Maintained by Dr. Vivek Karn Review process: editorial policy

Overview

Definition: Progressive Familial Intrahepatic Cholestasis (PFIC) refers to a group of rare, autosomal recessive genetic disorders characterized by impaired bile formation and secretion from hepatocytes, leading to chronic cholestasis, progressive liver damage, and often end-stage liver disease. The term "familial" refers to its inherited nature, and "progressive" highlights the deteriorating course of the disease if untreated.
Epidemiology: PFIC is a rare disease, with an estimated prevalence of 1 in 50,000 to 1 in 100,000 live births. It affects individuals worldwide, with no significant predilection for specific ethnic groups, although founder mutations can be observed in certain populations. Due to its rarity, diagnosis can be delayed.
Classification: PFIC is classified into several types based on the underlying genetic defect and the specific protein involved in bile acid transport. The main types, accounting for the majority of cases, include:
- PFIC Type 1 (PFIC1/Byler Disease): Caused by mutations in the ATP8B1 gene, encoding the familial intrahepatic cholestasis 1 (FIC1) protein, an aminophospholipid flippase.
- PFIC Type 2 (PFIC2): Caused by mutations in the ABCB11 gene, encoding the bile salt export pump (BSEP).
- PFIC Type 3 (PFIC3): Caused by mutations in the ABCB4 gene, encoding the multidrug resistance protein 3 (MDR3), responsible for phosphatidylcholine secretion into bile.
- PFIC Type 4 (PFIC4): Caused by mutations in the TJP2 gene, encoding tight junction protein 2.
- PFIC Type 5 (PFIC5): Caused by mutations in the NR1H4 gene, encoding the farnesoid X receptor (FXR).
- Other rare forms are continuously being identified.

Pathophysiology

Mechanism: The core mechanism involves defects in specific hepatobiliary transporters responsible for the efficient secretion of bile components from hepatocytes into the bile canaliculi.
- PFIC1 (ATP8B1/FIC1): FIC1 is involved in maintaining normal membrane lipid asymmetry and is crucial for the function of multiple bile acid transporters indirectly. Mutations lead to impaired bile flow, possibly due to altered membrane properties affecting transporter function, and increased susceptibility to cholestasis. It also has extrahepatic manifestations.
- PFIC2 (ABCB11/BSEP): BSEP is the primary transporter responsible for secreting conjugated bile acids from hepatocytes into the bile. ABCB11 mutations result in diminished or absent BSEP function, leading to accumulation of toxic bile acids within hepatocytes and progressively severe intrahepatic cholestasis.
- PFIC3 (ABCB4/MDR3): MDR3 transports phosphatidylcholine (PC) into the bile, where it forms mixed micelles with bile salts and cholesterol, protecting cholangiocytes from the detergent effects of bile salts. ABCB4 mutations cause reduced PC secretion, resulting in an increased proportion of unconjugated, hydrophobic bile salts in the bile that damage cholangiocytes, causing periductal inflammation and fibrosis.
- PFIC4 (TJP2): TJP2 is a tight junction protein. Mutations impair the integrity of tight junctions between hepatocytes, leading to paracellular leakage of bile components, increased permeability, and cholestasis.
- PFIC5 (NR1H4/FXR): FXR is a nuclear receptor crucial for regulating bile acid homeostasis. Mutations affect FXR's ability to regulate genes involved in bile acid synthesis, transport, and detoxification, leading to cholestasis.
Risk Factors:
- Autosomal Recessive Inheritance: Having two copies of a mutated gene (one from each parent) is the primary risk factor. Parents are typically asymptomatic carriers.
- Consanguinity: Higher incidence in populations with higher rates of consanguineous marriages due to increased likelihood of sharing recessive mutations.
Protective Factors: None identified, as the disease is genetic. Early diagnosis and appropriate management can mitigate progression and improve outcomes.

Clinical Presentation

Signs and Symptoms

Cardinal Features:
- Pruritus: Often severe and debilitating, typically the earliest and most distressing symptom, leading to excoriations and sleep disturbance. Varies in severity by type (e.g., usually severe in PFIC1 and PFIC2, milder or present late in PFIC3).
- Jaundice: Persistent or intermittent yellowing of the skin and sclera, usually appearing in infancy or early childhood.
- Growth Failure/Malnutrition: Due to malabsorption of fats and fat-soluble vitamins (A, D, E, K) secondary to cholestasis and chronic liver disease.
- Hepatomegaly and Splenomegaly: Enlargement of the liver and spleen due to chronic inflammation, fibrosis, and portal hypertension.
Early Signs:
- Neonatal or infantile onset of jaundice (often prolonged unconjugated and then conjugated hyperbilirubinemia).
- Severe, intractable pruritus.
- Pale stools (acholic stools) and dark urine.
- Failure to thrive.
Advanced Signs:
- Ascites and peripheral edema (due to portal hypertension and hypoalbuminemia).
- Variceal bleeding (from esophageal varices secondary to portal hypertension).
- Hepatic encephalopathy (rarely in late-stage).
- Xanthomas (cutaneous lipid deposits due to hypercholesterolemia, less common in PFIC but can occur).
- Steatorrhea.
- Complications of fat-soluble vitamin deficiencies (e.g., rickets, coagulopathy, night blindness).
- Cirrhosis and end-stage liver disease.
- Hepatocellular carcinoma (especially in PFIC2, even before cirrhosis).
Atypical Presentations:
- Some individuals with PFIC (particularly PFIC1 and mild ABCB4 mutations) may present later in childhood or even adulthood with milder symptoms or intermittent cholestasis.
- PFIC1 can have prominent extrahepatic features: severe watery diarrhea, sensorineural hearing loss, pancreatitis, and short stature.

Physical Examination

Inspection:
- Skin: Jaundice (scleral icterus, yellowish discoloration), excoriations from scratching, xanthomas (rare). Pale skin (anemia).
- Abdomen: Distended abdomen (hepatosplenomegaly, ascites). Visible superficial veins (caput medusae in portal hypertension).
- General: Poor growth, muscle wasting, signs of fat-soluble vitamin deficiencies (e.g., skeletal deformities from rickets, bruising from vitamin K deficiency).
Palpation:
- Abdomen: Firm, enlarged liver (hepatomegaly), enlarged spleen (splenomegaly). Tense ascites.
Special Tests:
- Neurological examination: May reveal signs of hepatic encephalopathy in advanced disease, though less common in childhood.
- Auditory Brainstem Response (ABR): Can be used to screen for sensorineural hearing loss in PFIC1.

Diagnostic Approach

History Taking

Key Questions:
- Onset of symptoms: When did jaundice, pruritus, or pale stools first appear? Was it in the neonatal period?
- Family history: Any history of cholestasis, liver disease, or unexplained infant deaths in the family? Parental consanguinity?
- Growth and development: Is the child gaining weight and height appropriately? Any developmental delays?
- Stool and urine color: Pale/acholic stools, dark urine.
- Pruritus characteristics: Severity, timing (worse at night), impact on sleep.
- Extrahepatic symptoms: Diarrhea, hearing problems, pancreatitis (especially for PFIC1).
- Medications and diet: Any relevant exposures.
Red Flags:
- Early onset intractable pruritus and jaundice persisting beyond the neonatal period.
- Family history suggestive of an inherited liver disorder.
- Rapid progression of liver dysfunction or failure to thrive.
- Signs of portal hypertension at an early age.

Laboratory Tests

First-Line:
- Liver Function Tests (LFTs):
  - Conjugated (Direct) Hyperbilirubinemia: Typically >20% of total bilirubin or >1.0 mg/dL (17 µmol/L).
  - Elevated Serum Bile Acids: Markedly elevated, often 10-100 times normal. This is a hallmark of cholestasis.
  - Gamma-Glutamyl Transferase (GGT): Crucial for differentiating PFIC types:
    - Normal or Low GGT: Highly suggestive of PFIC1 or PFIC2.
    - Markedly Elevated GGT: Suggests PFIC3 or other forms of cholestasis (e.g., Alagille syndrome, biliary atresia), but can also be normal or low in specific ABCB4 mutations.
  - Elevated Alkaline Phosphatase (ALP): Also elevated in cholestasis, but less discriminatory than GGT for PFIC types.
  - Aminotransferases (AST/ALT): Mild to moderate elevation, typically <5 times upper limit of normal, but can be higher in acute phases or severe disease.
- Coagulation Profile (PT/INR): Often prolonged due to vitamin K malabsorption and impaired hepatic synthesis.
- Serum Albumin: May be decreased in advanced disease.
- Serum Cholesterol: Variable; can be normal or slightly elevated.
- Fat-soluble vitamin levels (A, D, E, K): Often deficient and require monitoring.
- Serum alpha-fetoprotein (AFP): May be elevated, particularly in PFIC2, even in the absence of obvious HCC.
Confirmatory:
- Genetic Testing: Gold standard for definitive diagnosis. Targeted gene panels for ATP8B1, ABCB11, ABCB4, TJP2, NR1H4, and other candidate genes (next-generation sequencing panels). This confirms the subtype and assists in prognostication and treatment planning.
- Liver Biopsy: Essential for histopathological assessment where genetic testing is not immediately available or to assess disease severity and exclude other causes.
  - PFIC1: Non-specific cholestasis, often mild inflammation, early centrolobular cholestasis, giant cell transformation. Ultrastructural studies may show characteristic abnormalities of canalicular membranes. Immunostaining for BSEP is normal.
  - PFIC2: Absence or markedly reduced BSEP staining on canalicular membranes (immunohistochemistry on liver biopsy). Severe progressive cholestasis, often with necroinflammation and early progression to fibrosis/cirrhosis. HCC association.
  - PFIC3: Ductuolar proliferation, portal inflammation, fibrosis, and pericholangitis (resembles biliary atresia in some aspects), with normal or decreased MDR3 staining on canalicular membranes.
  - Note: Biopsy findings can be overlapping or non-specific, particularly in early stages.
- Bile analysis: Direct measurement of bile phospholipid/bile salt ratio (low in PFIC3) can be difficult to obtain but is highly specific.
Monitoring:
- Regular LFTs, bilirubin, bile acids, fat-soluble vitamins, nutritional status.
- Routine screening for hepatocellular carcinoma (HCC) in PFIC2 (alpha-fetoprotein and abdominal ultrasound every 3-6 months, starting at diagnosis).
- Monitoring for complications of portal hypertension (e.g., endoscopy for varices).

Imaging

Recommended:
- Abdominal Ultrasound: First-line imaging. To exclude extrahepatic biliary obstruction (e.g., biliary atresia, choledochal cyst). Typically shows intrahepatic cholestasis without dilated bile ducts; may show hepatosplenomegaly, portal hypertension signs (e.g., ascites, splenomegaly, collateral vessels).
- Magnetic Resonance Cholangiopancreatography (MRCP): Can be used to confirm patency of the biliary tree and rule out structural anomalies if ultrasound is inconclusive. Not usually diagnostic for PFIC types themselves but crucial for differential diagnosis.
Advanced:
- Liver Elastography (e.g., FibroScan): Non-invasive assessment of liver fibrosis, used for monitoring disease progression and response to therapy.
- Computed Tomography (CT) or MRI with contrast: Used in cases of suspected HCC or for more detailed assessment of liver morphology.

Management

Acute Management

Immediate: Address complications such as coagulopathy due to vitamin K deficiency (administer parenteral vitamin K), severe pruritus, and dehydration.
Stabilization:
- Nutritional Support: Ensure adequate caloric intake with medium-chain triglycerides (MCT) to bypass bile salt-dependent absorption. Supplementation with fat-soluble vitamins (A, D, E, K) is crucial, often requiring higher doses than standard.
- Management of Pruritus:
  - Rifampicin: Induces cytochrome P450 enzymes, which metabolize bile acids, reducing systemic levels. Dose: 5-10 mg/kg/day orally in 1-2 divided doses (max 300-600 mg/day). Monitor liver enzymes.
  - Cholestyramine (or other bile acid sequestrants): Binds bile acids in the gut, interrupting enterohepatic circulation. Dose: 0.25-0.5 g/kg/day orally in 2-3 divided doses. Administer separately from other medications (at least 1 hour before or 4-6 hours after) to prevent malabsorption.
  - Ursodeoxycholic Acid (UDCA): While often attempted, UDCA is generally ineffective in PFIC1 and PFIC2 due to defects in bile acid transport itself. It may be partially effective in PFIC3, especially in milder mutations, by increasing phosphatidylcholine secretion and providing cytoprotection. Dose: 10-15 mg/kg/day in 2-3 divided doses.
  - Sertraline: For chronic, severe pruritus unresponsive to first-line agents, 0.5-2 mg/kg/day.
  - Albumin dialysis (e.g., MARS): May be considered in refractory severe pruritus with significant distress, as a bridge to liver transplantation or surgical diversion.
Emergency: Management of variceal bleeding (endoscopic banding/sclerotherapy) and other complications of portal hypertension.

Chronic Management

Pharmacological:
- Ursodeoxycholic Acid (UDCA): As above, most effective in PFIC3, potentially in some TJP2 or NR1H4 mutations, but generally ineffective alone in PFIC1/2.
- Rifampicin/Cholestyramine: For pruritus management as described above.
- Novel therapies:
  - Ileal Bile Acid Transporter (IBAT) inhibitors (e.g., odevixibat, maralixibat): Reduce bile acid reabsorption from the ileum, decreasing systemic bile acid levels and pruritus. Approved for PFIC types 1, 2, and other cholestatic conditions. Dosing is weight-based.
  - Future therapies: Gene therapy, chaperone therapy, or small molecule modulators targeting specific protein defects are under investigation.
Non-pharmacological:
- Nutritional Support: Ongoing management of fat-soluble vitamin deficiencies (high-dose supplementation of A, D, E, K) and caloric support (MCT oil supplementation, high-calorie diet). Regular monitoring of levels and clinical signs of deficiency.
- Surgical diversions:
  - Partial External Biliary Diversion (PEBD) or Partial Internal Biliary Diversion (PIBD): Surgical procedures to divert a portion of bile away from the enterohepatic circulation to reduce the bile acid pool.
    - PEBD: Bile is diverted to a stoma on the abdominal wall. Requires careful management of fluid/electrolyte loss and stoma care. Highly effective for pruritus in selected patients with PFIC1 and particularly PFIC2, and can delay progression to liver failure.
    - PIBD: Ileal bypass or creation of a blind ileal loop to disrupt enterohepatic circulation internally. Less common than PEBD.
  - Indications for diversion: Severe pruritus unresponsive to maximal medical therapy, progressive liver disease, without advanced cirrhosis, and preserved synthetic function. Patients with high GGT (PFIC3) generally respond poorly due to ongoing ductular damage.
Monitoring:
- Regular clinical assessment for growth, pruritus, signs of liver disease progression.
- Laboratory monitoring (LFTs, bilirubin, bile acids, fat-soluble vitamins, coagulation profile) every 3-6 months.
- Imaging (ultrasound, elastography) to assess liver size, portal hypertension, and fibrosis progression.
- HCC surveillance: Every 3-6 months with alpha-fetoprotein and ultrasound for PFIC2 patients and after cirrhosis develops in other types.
- Bone density monitoring for vitamin D deficiency-related bone disease.

Treatment Algorithms

First-Line:
1. Diagnosis and Counseling: Confirm PFIC type via genetic testing. Genetic counseling for families.
2. Nutritional Support: Aggressive nutritional support (MCT, fat-soluble vitamins A, D, E, K).
3. Pruritus Management: Rifampicin, cholestyramine, IBAT inhibitors (odevixibat/maralixibat) if available and indicated. UDCA for PFIC3.
Second-Line:
1. If medical management fails to control pruritus or prevent disease progression (e.g., worsening liver function, persistent jaundice, growth failure, early signs of portal hypertension, or persistent high bile acids despite IBAT inhibitors): Consider surgical biliary diversion (PEBD). Careful patient selection is crucial: best outcomes in PFIC1 and PFIC2, less effective in PFIC3.
Refractory Cases:
1. Liver Transplantation: Indicated for:
  - End-stage liver disease (cirrhosis, synthetic dysfunction, refractory portal hypertension).
  - Intractable, debilitating pruritus unresponsive to all other measures.
  - Development of hepatocellular carcinoma, particularly in PFIC2.
  - Failure of growth and profound malnutrition not salvageable by other means.
  - PFIC1: Recurrence of disease (cholestasis, severe diarrhea, or other extrahepatic manifestations) can occur in the transplanted liver or small bowel due to the ubiquitous expression of FIC1, making transplant an individualized decision.
  - PFIC2: PFIC2 does not recur in the transplanted liver. However, anti-BSEP antibodies can develop in about 20% of cases, leading to graft failure, and a re-transplant may be needed.
  - PFIC3: Does not recur in the transplanted liver.

Complications

Common:
- Severe Pruritus: Leading to excoriations, skin infections, sleep disturbance, impaired quality of life.
- Malnutrition and Growth Failure: Due to fat malabsorption and increased metabolic demands.
- Fat-soluble Vitamin Deficiencies:
  - Vitamin K: Coagulopathy and bleeding.
  - Vitamin D: Rickets, osteopenia/osteoporosis.
  - Vitamin A: Night blindness, xerophthalmia.
  - Vitamin E: Neuropathy, hemolytic anemia.
- Cholelithiasis (Gallstones): Impaired bile flow can lead to stone formation.
- Recurrent Cholangitis: Particularly in PFIC3 with ductal damage.
Serious:
- Cirrhosis and Hepatic Failure: Progressive liver damage leading to end-stage liver disease.
- Portal Hypertension and its complications: Variceal bleeding, ascites, splenomegaly, hepatic encephalopathy.
- Hepatocellular Carcinoma (HCC): Particularly high risk in PFIC2, often developing in early childhood even before significant cirrhosis is evident. Less common but can occur in prolonged cholestasis of other types.
- Recurrence of Cholestasis Post-Transplant: Can occur in some PFIC1 patients due to systemic FIC1 deficiency, or with anti-BSEP antibodies in PFIC2 patients.
Long-term:
- Chronic debilitating pruritus.
- Need for lifelong nutritional and vitamin supplementation.
- Increased risk of liver transplantation.
- Extrahepatic manifestations (e.g., pancreatitis and hearing loss in PFIC1).
- Reduced quality of life for patients and families.

Prognosis

Factors:
- Type of PFIC: PFIC2 typically has the most aggressive course, often leading to liver failure or HCC in early childhood. PFIC1 also progresses rapidly to liver failure. PFIC3 has a more variable course; some milder cases may respond to UDCA and have a slower progression, while others require transplant.
- Severity of Genetic Mutation: Null mutations usually predict a more severe phenotype.
- Age at Onset: Earlier onset generally correlates with more rapid progression.
- Response to Medical/Surgical Therapy: PRURITUS control and improved nutritional status can significantly impact quality of life and disease progression.
- Development of Complications: Especially HCC, which significantly worsens prognosis.
Survival: Without intervention, many individuals with PFIC1 and PFIC2 progress to end-stage liver disease and hepatic failure by adolescence or early adulthood. Liver transplantation offers significantly improved survival, although long-term outcomes depend on post-transplant complications and recurrence if any.
Quality of Life: Significantly impacted by chronic pruritus, nutritional deficiencies, and frequent medical interventions. Successful management and timely transplantation can greatly improve quality of life. Extrahepatic manifestations also contribute.

Prevention

Primary: Not preventable as it is a genetic disorder. Genetic counseling for families identified with a gene mutation is important to understand recurrence risk for future pregnancies.
Secondary:
- Early Diagnosis: Crucial for initiating treatment promptly to slow disease progression and prevent severe complications. Newborn screening for PFIC is not performed routinely but may be considered in research settings.
- Genetic Screening: For at-risk siblings of an affected child or for carriers in affected families, for family planning.
Tertiary:
- Aggressive Management: Of pruritus, nutritional deficiencies, and cholestasis to prevent or delay the onset of cirrhosis and its complications.
- Regular Surveillance: For HCC, especially in PFIC2, and for complications of portal hypertension.
- Timely Referral for Liver Transplantation: Before decompensation and severe malnutrition make transplantation riskier.

Special Populations

Pediatric: PFIC is primarily a pediatric disease, with most presentations occurring in infancy or early childhood. Nutritional management, monitoring of growth and development, and specific considerations for surgical diversion and transplantation unique to children (e.g., living donor transplantation) are central.
Geriatric: Extremely rare for PFIC to first present in geriatric age, as it is a progressive disease usually diagnosed in childhood. However, individuals with milder mutations or atypical presentations might survive into adulthood without transplant and may experience age-related complications alongside chronic liver disease.
Pregnancy: Females with PFIC reaching reproductive age are rare, especially without transplantation. Pregnancy would be high-risk due to pre-existing liver disease and potential for exacerbation of cholestasis. Pregnancy in a transplant recipient needs careful management of immunosuppression.
Comorbidities:
- PFIC1 and Extrahepatic Manifestations: Co-management of severe watery diarrhea, sensorineural hearing loss, and pancreatitis is required.
- Other genetic conditions: Rule out other genetic causes of cholestasis like Alagille syndrome.
- Renal tubular acidosis: Can occur in some cholestatic conditions; requires monitoring.

Clinical Pearls

Diagnostic:
- GGT is key: In a cholestatic infant/child, a normal or low serum GGT strongly points to PFIC1 or PFIC2, or some forms of Byler's Syndrome. High GGT strongly suggests PFIC3 or other forms of cholestasis.
- Genetic testing is definitive: Do not delay genetic testing. It confirms diagnosis, guides prognosis, and informs therapy (e.g., UDCA trial for PFIC3).
- Liver biopsy can be misleading: Histology can be non-specific, especially in early disease. Immunostaining for BSEP/MDR3 on biopsy is helpful but not always diagnostic due to heterogeneity.
Treatment:
- Pruritus relief is paramount: Severe pruritus significantly impacts quality of life. Aggressive medical (rifampicin, IBAT inhibitors) or surgical (PEBD) intervention should be considered early.
- Nutritional support is critical: Ensure adequate intake of calories and fat-soluble vitamins to support growth and prevent long-term complications.
- Consider PEBD early: For well-selected patients with PFIC1/2, PEBD can delay or prevent the need for liver transplantation by effectively reducing systemic bile acid levels.
- HCC surveillance in PFIC2: Start early and continue lifelong, even after partial diversion.
Pitfalls:
- Misdiagnosing as biliary atresia: Imaging of PFIC shows no dilated ducts, mimicking biliary atresia. Liver biopsy and GGT levels help differentiate.
- Delaying specialized care: PFIC is a complex disease requiring management by a multidisciplinary team at a specialized pediatric hepatology center.
- Underestimating the impact of pruritus: It can be severely debilitating and requires aggressive, sustained intervention.
- Missing extrahepatic manifestations in PFIC1: Diarrhea, hearing loss, and pancreatitis need specific attention.
- Failure to screen for HCC in PFIC2: This can lead to late diagnosis of a highly aggressive cancer.
- Starting UDCA in PFIC1/2: Generally ineffective and can delay more appropriate treatments.

Recent Updates

Guidelines: The European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Consensus Guidelines for the Diagnosis and Management of Progressive Familial Intrahepatic Cholestasis (PFIC) provide comprehensive recommendations. (Updated 2020-2022 by various groups).
Evidence:
- IBAT Inhibitors: Recent clinical trials (e.g., A452-CL-001 (PEDFIC-1), A452-CL-002 (PEDFIC-2) for odevixibat; ICONIC study for maralixibat) have demonstrated the efficacy of ileal bile acid transporter (IBAT) inhibitors in reducing pruritus and bile acid levels in various PFIC types, particularly PFIC1 and PFIC2. Odevixibat (Bylvay) is now approved for PFIC types 1, 2, and other cholestatic conditions in several regions.
- Genetic characterization: Ongoing identification of new PFIC genes and better understanding of phenotypic variability helps improve diagnostic accuracy and prognostication.
- Improved understanding of BSEP anti-body mediated graft failure: Research continues into prevention and management strategies for anti-BSEP antibodies post-liver transplant in PFIC2.
Controversies:
- Optimal timing and selection for biliary diversion vs. transplantation: The decision-making process for surgical interventions remains complex and individualized, weighing risks of surgery against the benefits of delaying transplant.
- Long-term efficacy and safety of new therapies: While promising, the long-term impact of IBAT inhibitors on liver disease progression and the potential for new side effects are still being evaluated.
- Management of PFIC1 post-transplant recurrence: Optimal strategies for managing recurrence of cholestasis or extrahepatic symptoms in post-transplant PFIC1 patients are still evolving.

Key References

Guidelines:
- European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Position Paper: Clinical Practice Guidelines for the Diagnosis and Management of Progressive Familial Intrahepatic Cholestasis. (Refer to the most recent publication for specific dates, typically 2020-2022).
- American Association for the Study of Liver Diseases (AASLD) and European Association for the Study of the Liver (EASL) guidelines on cholestatic liver diseases (though not PFIC-specific, they contain relevant information).
Studies:
- PEDFIC-1 and PEDFIC-2 Studies: Clinical trial data on odevixibat (Bylvay) for PFIC; published in major gastroenterology/hepatology journals (e.g., Hepatology, Journal of Hepatology).
- ICONIC Study: Clinical trial data on maralixibat for PFIC, Alagille Syndrome; published similarly.
- Landmark studies on genetic basis of PFIC: Original publications identifying ATP8B1, ABCB11, and ABCB4 genes (e.g., publications in Nature Genetics, American Journal of Human Genetics).
Reviews:
- Current reviews on Progressive Familial Intrahepatic Cholestasis: Search PubMed/Medline for recent comprehensive reviews in journals like Liver International, Ailmentary Pharmacology & Therapeutics, Gastroenterology, and Hepatology Communications.

Disclaimer: This information is intended for educational purposes only and does not constitute medical advice. It is crucial for healthcare professionals to exercise independent clinical judgment and consult official guidelines, recent literature, and specialists when making decisions regarding patient care. Progressive Familial Intrahepatic Cholestasis is a complex and rare disorder that requires management by a specialized multidisciplinary team. Dosages and treatment approaches may need to be individualized.